Repatha vs Amlodipine: Head-to-Head Efficacy Compared

Why Comparing These Two Drugs Requires Context

Repatha and amlodipine are not rivals. They address separate risk factors: elevated LDL cholesterol and elevated blood pressure. A direct head-to-head randomized trial comparing the two drugs does not exist and, from a trial-design standpoint, would be hard to justify ethically given that both are guideline-recommended for distinct indications.

The comparison that matters clinically is: for a given patient's predominant risk driver, which drug contributes more to reducing cardiovascular outcomes? That question has real-world weight, because both atherosclerotic cardiovascular disease (ASCVD) and hypertension are independent, additive risk factors. The ACC/AHA 2019 Primary Prevention Guideline states that "hypertension, dyslipidemia, diabetes, and smoking are the primary risk factors for ASCVD," treating them as a parallel list rather than a hierarchy. [1]

The Different Biological Pathways

Evolocumab blocks PCSK9, a protein that degrades LDL receptors on hepatocytes. Fewer PCSK9 molecules means more LDL receptors recycle to the cell surface, pulling more LDL particles out of circulation. [2] The net effect is a 59% reduction in LDL-C on top of statin therapy, as seen in FOURIER. [3]

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac tissue, causing arterial dilation and a drop in systemic vascular resistance. [4] The result is sustained 24-hour blood pressure control without the bradycardia and bronchospasm associated with beta-blockers.

Why Both Risk Factors Demand Treatment

A 1 mmol/L reduction in LDL-C reduces major vascular events by about 22% over 5 years, according to the Cholesterol Treatment Trialists' (CTT) meta-analysis of 170,000 participants. [5] A 10 mmHg reduction in systolic blood pressure cuts major cardiovascular events by roughly 20%, per the Blood Pressure Lowering Treatment Trialists' Collaboration meta-analysis (N=348,854). [6] Neither intervention substitutes for the other.

FOURIER Trial: What Evolocumab Actually Proved

FOURIER enrolled 27,564 patients with established ASCVD who were already on optimized statin therapy. Adding evolocumab 140 mg every two weeks or 420 mg monthly versus placebo over a median follow-up of 2.2 years produced the following results. [3]

Primary and Secondary Endpoints

The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group, a 15% relative risk reduction (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001). [3]

The key secondary endpoint (cardiovascular death, MI, or stroke) showed a 20% relative risk reduction (HR 0.80; 95% CI 0.73 to 0.88; P<0.001). [3] Absolute LDL-C dropped from a median of 92 mg/dL to 30 mg/dL, a 59% reduction. [3]

Importantly, the benefit was not uniform across time. A pre-specified analysis published in Circulation showed that MACE risk reduction increased from 16% in year one to 25% in years two and beyond, suggesting that atherosclerotic plaque regression compounds over time. [7]

Who Benefits Most in FOURIER

Patients with prior MI had a 19% reduction in the key secondary endpoint. Those with multiple prior MIs saw even larger absolute risk reductions. [3] The trial excluded patients without established ASCVD, so FOURIER does not establish benefit for primary prevention, a distinction the FDA label preserves. [8]

ASCOT-BPLA Trial: What Amlodipine Proved

ASCOT-BPLA randomized 19,257 hypertensive patients (systolic BP 160 to 179 mmHg or diastolic BP 100 to 109 mmHg, plus at least three CV risk factors) to amlodipine-based therapy (amlodipine 5 to 10 mg, with perindopril added if needed) versus atenolol-based therapy (atenolol 50 to 100 mg, with bendroflumethiazide added if needed). [9]

Why ASCOT-BPLA Was Stopped Early

The trial was halted early after a median follow-up of 5.5 years because the amlodipine arm showed significantly better outcomes. [9] Fatal and nonfatal stroke was 23% lower in the amlodipine group (HR 0.77; 95% CI 0.66 to 0.90; P=0.0003). Total cardiovascular events and procedures were 16% lower (HR 0.84; 95% CI 0.78 to 0.90; P<0.0001). [9]

All-cause mortality was 11% lower in the amlodipine-treated patients (HR 0.89; 95% CI 0.81 to 0.99; P=0.025). [9] The atenolol arm also experienced significantly more new-onset diabetes (relative risk 1.30; P<0.0001), making amlodipine the metabolically safer choice.

What ASCOT-BPLA Does Not Tell Us

ASCOT-BPLA was an active comparator trial against atenolol, not a placebo-controlled trial. The cardiovascular benefit observed partially reflects the harm from atenolol rather than an absolute effect of amlodipine alone. [9] the JNC-8 panel and ESC/ESH 2023 Hypertension Guidelines both recommend calcium channel blockers as first-line options for most hypertensive patients, grounded in consistent event-reduction data across multiple trials. [10]

LDL Reduction vs Blood Pressure Reduction: Which Matters More?

The answer depends on the individual patient's risk profile. Neither therapy is universally superior.

When LDL Is the Bigger Driver

A patient with established ASCVD (prior MI, stroke, or symptomatic PAD), LDL-C above 70 mg/dL despite maximally tolerated statin therapy, and well-controlled blood pressure gains more from adding a PCSK9 inhibitor than from intensifying antihypertensive therapy. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction specifically recommends PCSK9 inhibitors as class I for patients with ASCVD and LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe. [11]

The Mendelian randomization data support this directionally. A study in the European Heart Journal analyzing 300,000 participants found that each 38.7 mg/dL lower LDL-C (equivalent to a PCSK9 variant effect) was associated with a 29% lower risk of coronary heart disease (OR 0.71; 95% CI 0.65 to 0.78). [12]

When Blood Pressure Is the Bigger Driver

A patient with stage 2 hypertension (systolic BP ≥140 mmHg) but LDL-C already at goal on a statin benefits more from effective antihypertensive treatment. The SPRINT trial (N=9,361) demonstrated that targeting systolic BP <120 mmHg versus <140 mmHg reduced fatal and nonfatal major cardiovascular events by 25% (HR 0.75; 95% CI 0.64 to 0.89; P<0.001). [13] Amlodipine was used in 77% of intensive-arm patients in SPRINT, making it the most common agent in that benefit signal. [13]

When Both Are Needed

The ASCOT-LLA sub-study embedded within ASCOT-BPLA randomized 10,305 participants with hypertension and total cholesterol ≤6.5 mmol/L to atorvastatin 10 mg versus placebo. [14] Fatal coronary heart disease or nonfatal MI fell by 36% (HR 0.64; 95% CI 0.50 to 0.83; P=0.0005). [14] Combining antihypertensive and lipid-lowering therapy produced additive risk reduction, and the benefit was greater in the amlodipine arm than the atenolol arm of the host trial, suggesting a favorable pharmacological combination between calcium channel blockers and statins at the vascular wall level. [14]

Safety Profiles Compared

Evolocumab (Repatha) Safety

Evolocumab is a subcutaneous biologic injection given every two weeks or monthly. In FOURIER, injection-site reactions occurred in 2.1% of patients. Neurocognitive adverse events were not significantly different from placebo (2.2% vs 1.8%). [3] The FDA label carries no black-box warning. [8] Cataracts and new-onset diabetes showed no statistically significant excess versus placebo over the 2.2-year median follow-up.

Contraindications are few: known hypersensitivity to evolocumab, and relative caution in pregnancy due to limited data. Cost is a practical barrier. Without insurance, the list price exceeds $500 per month; copay assistance programs bring this to $0 for most commercially insured patients. [8]

Amlodipine Safety

Amlodipine's most common adverse effect is peripheral edema, affecting 10.8% of patients at 10 mg per day in controlled trials. [4] The edema is dose-dependent and results from precapillary arterial dilation without matching venular dilation. Switching from amlodipine to an ACE inhibitor combination (amlodipine/perindopril) reduces edema rates substantially. [15]

Amlodipine does not significantly lower heart rate, which differentiates it from beta-blockers and diltiazem, and makes it safe in patients with reactive airway disease. [4] No meaningful renal dose adjustment is required. Generic amlodipine costs under $10 per month at most pharmacies.

Can These Drugs Be Combined?

Yes. They treat orthogonal targets and have no pharmacokinetic interaction of clinical significance. CYP3A4 inhibitors (clarithromycin, ketoconazole) can raise amlodipine plasma levels by up to 40%, but evolocumab, a biologic, is not metabolized by cytochrome P450 enzymes and does not interact with amlodipine through that pathway. [4][8]

In clinical practice, patients with established ASCVD and coexisting hypertension commonly receive a statin, a PCSK9 inhibitor, an ACE inhibitor or ARB, and a calcium channel blocker concurrently. The ACCOMPLISH trial (N=11,506) showed that the combination of benazepril plus amlodipine reduced MACE by 20% compared to benazepril plus hydrochlorothiazide, supporting amlodipine-based regimens as the antihypertensive backbone in high-risk patients. [16]

The following clinical decision framework summarizes which drug to prioritize based on the patient's primary untreated risk driver:

| Primary Uncontrolled Risk Factor | LDL-C ≥70 mg/dL on max statin | BP ≥130/80 mmHg on current regimen | Both elevated | |---|---|---|---| | Established ASCVD | Add evolocumab (Class I, ACC/AHA 2022) | Add/intensify CCB or RAS blocker | Add both | | Primary prevention, high risk | Consider evolocumab if 10-yr risk ≥20% and LDL persistently elevated | Initiate amlodipine per JNC-8 | Treat both simultaneously | | Primary prevention, moderate risk | Statin intensification preferred over PCSK9i | Amlodipine first-line | Statin + amlodipine |

Dosing and Administration

Evolocumab Dosing

The FDA-approved dosing for evolocumab is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly. [8] Both regimens produce equivalent LDL-C reductions at steady state. The SureClick autoinjector and the Pushtronex monthly device are the two delivery options. Patients can self-inject at home after initial training. The drug requires refrigeration at 2 to 8 degrees Celsius but can be stored at room temperature up to 77 degrees Fahrenheit for up to 30 days.

Amlodipine Dosing

Amlodipine starts at 5 mg orally once daily for most adults and can be titrated to 10 mg after 7 to 14 days if BP remains uncontrolled. [4] In elderly patients or those with hepatic impairment, the starting dose is 2.5 mg to minimize hypotension risk. The long half-life of 30 to 50 hours provides stable 24-hour coverage from a once-daily dose. [4]

Guideline Positions on Each Drug

The ACC/AHA 2022 Guideline for the Management of Blood Cholesterol states: "In patients with clinical ASCVD in whom LDL-C level remains ≥70 mg/dL despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor (Class IIa, LOE A)." When the 10-year ASCVD risk is very high, the recommendation strengthens to Class I. [11]

For hypertension, the ACC/AHA 2017 Hypertension Guideline recommends thiazide-type diuretics, ACE inhibitors, ARBs, or dihydropyridine CCBs (including amlodipine) as first-line agents in most patients. [17] The ESC/ESH 2023 Hypertension Guidelines similarly list amlodipine as a preferred CCB based on outcome trial data, citing ASCOT-BPLA specifically as a source of its class IA recommendation. [10]

Neither guideline frames these two drugs as alternatives. They appear in separate sections addressing different risk factors.

Cost-Effectiveness Considerations

A 2019 JAMA Cardiology analysis modeled the cost-effectiveness of evolocumab in FOURIER-eligible patients. At the then-current list price, the cost per quality-adjusted life year (QALY) was approximately $450,000, well above the conventional $150,000 threshold. [18] After Amgen reduced the list price from $14,523 to $5,850 per year in 2018, an updated analysis estimated the cost per QALY fell to roughly $60,000 to $100,000, entering a cost-effective range for patients with established ASCVD and very high cardiovascular risk. [18]

Amlodipine as generic is among the lowest-cost antihypertensive agents available, well under $200 per year at standard doses. Outcome data per dollar spent favors amlodipine strongly for hypertensive patients. The choice between them is not a financial trade-off for most patients, since their indications rarely overlap directly.

What Real Patients Ask Their Clinicians

Patients searching "Repatha vs amlodipine" are often trying to understand whether a new prescription is redundant, or whether one drug can replace another. The direct answer: no drug in this comparison replaces the other. A clinician who prescribes amlodipine is treating blood pressure; a clinician who prescribes evolocumab is treating residual LDL-related ASCVD risk on top of statin therapy. [11][17] These are different biological problems requiring different solutions.

Patients who have recently received a PCSK9 inhibitor prescription and are already on amlodipine should not discontinue amlodipine. Conversely, a patient started on amlodipine for new hypertension who already takes Repatha should continue Repatha per their lipid management plan.